AlphaMadera's AlphaVal page classifies Nutrien Ltd. as a Cyclical & Capital-Intensive business and values it using Normalized Earnings × Cycle Multiple, then compares the result to the current market price to flag NTR as undervalued, fairly valued, or overvalued.

What is Nutrien Ltd.'s fair value?

Fair value for NTR comes from a Normalized Earnings × Cycle Multiple model -- the approach AlphaVal selected for this company's Cyclical & Capital-Intensive classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value NTR?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. NTR was classified as Cyclical & Capital-Intensive and is valued using Normalized Earnings × Cycle Multiple, built from NTR's most recent reported fundamentals.

NTR - Nutrien Ltd.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $77.29 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Cyclical & Capital-Intensive 80% confidence

Primary model: Normalized Earnings × Cycle Multiple

Valuation Signal Overvalued Strong

Trading 54.9% above fair value

Current Price $69.74

Bear Case $33.18 52.4% downside ($33.18 - $69.74) / $69.74 = -52.4% $4.74 × 7x

Fair Value $45.03 35.4% downside ($45.03 - $69.74) / $69.74 = -35.4% $4.74 × 10x

Bull Case $56.88 18.4% downside ($56.88 - $69.74) / $69.74 = -18.4% $4.74 × 12x

Adjust Assumptions

Cycle P/E Multiple

9.5x

Normalized EPS

4.74$

Key Value Driver

Through-cycle normalized EPS ($4.74)

Terminal Value % of EV

Implied Market Multiple 14.7x

Market is pricing in (growth)

Plain-Language Summary

Using 7-year normalized EPS of $4.74 at a 10x cycle multiple, the base-case value is $45.03 per share. P/TBV cross-check: 2.9x.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (33 analysts) $77.29

Analyst Range $65.00 – $90.00

Divergence from AlphaVal 42%

Warnings

⚠ This company has a built-in lending arm whose debt is mixed in with the main business. We capped the debt adjustment to avoid overstating what the core business owes.

⚠ Price-to-book value of 2.9x is above the normal range for this type of business (0.7x-2.0x). The stock may already price in a strong cycle.

ℹ Wall Street's average price target is $77.29 (from 33 analysts). Our estimate is 42% below the consensus -- consider that gap carefully.

Key Risks

Standard 10-year DCF produces unreliable terminal values for cyclicals
'Cheap' P/E at cycle peak is the most common value trap — normalize first
Captive finance subsidiaries have different risk profiles from manufacturing